Proshares Trust ZBIO
ZBIO
$28.08 -0.10 (-0.35%)
At close: Oct 21, 2026 · 4:00 PM EDT

Zenas BioPharma (ZBIO) EBITDA Margin (2024 - 2026)

Updated

Zenas BioPharma's EBITDA Margin came in at -10765.50% for Q2 2026.

Analysis

Zenas BioPharma (ZBIO) EBITDA Margin (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Zenas BioPharma reported EBITDA Margin of -47554.20%, down 46294.23 percentage points year-over-year; for FY2025, it was -3830.01%, down 554.99 percentage points from FY2024.

  • Going back by year, EBITDA Margin was -3275.02% in FY2024 (-3200.95 pp) and -74.07% in FY2023.
  • The Q2 2026 figure represents the highest quarterly EBITDA Margin since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Zenas BioPharma 1.77 Bn 1.09 Bn - -10,894.20%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10,894.20%
Mar 31, 2025 -376.89%
Dec 31, 2024 -1,111.80%
API Access

Zenas BioPharma EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ZBIO&period=max&api_key=YOUR_API_KEY